ISMP is currently seeking public comment on the revised ISMP’s Guidelines for the Safe Use of Automated Dispensing Cabinets (ADCs) through August 31, 2018 and would appreciate review by our MSOS members. Now it’s your chance to view the revised ADC Guidelines and provide feedback at: https://www.ismp.org/resources/revised-guidelines-safe-use-automated-dis.... Also, a special thank you to those members who, as part of an expert advisory group, provided input for this revision.
The preliminary comparative data from the ISMP Medication Safety Self Assessment® for High-Alert Medications is now available online to participants who submitted their findings to ISMP. The quality improvement workbook contains aggregate data that can be used by participants to compare their results to the aggregate results of demographically similar US facilities. Inpatient, outpatient, and prioritization worksheets are provided.
Shedding Light on a Black Hole: Local Anesthetic Use in the Pediatric OR
Meghan Rowcliffe PharmD, BCPS, BCPPS Medication Safety Officer, Pediatrics The Johns Hopkins Hospital
Avoiding harm: A Focus on the REMS Program for alemtuzumab (Lemtrada)
Jamie Wilkins, PharmD
Deputy Director, Division of Risk Management, Office of Medication Error Prevention and Risk Management, Office of Surveillance and Epidemiology, CDER, FDA
Update on the ISMP Smart Infusion Pump Summit
Michelle Mandrack, MSN, Director of Consulting Services, ISMP
David Valentine, PharmD, 2017-2018 ISMP Safe Medication Management Fellow
Update from ISMP
Michael Cohen, RPh, MS, ScD (hon), DPS (hon), FASHP, President, ISMP
Sign up now for the next MSOS Member Briefing webinar scheduled to be held on Thursday, June 28, 2018 from 1:00-2:00 pm ET.
Short medication safety-related presentations for this webinar will include:
A National Alert Network (NAN) alert was recently sent out regarding the safe handling of concentrated electrolyte products from outsourcing facilities during critical drug shortages. These products, particularly concentrated potassium chloride, may be provided by outsourcing facilities in syringes or vials without the same labeling required by USP for commercially available products. Special precautions should be taken to prevent these products from being dispensed from the pharmacy undiluted, and inadvertently administered which could result in a fatality. Please share this alert with your staff and colleagues. https://www.ismp.org/sites/default/files/attachments/2018-05/NAN%20Alert%2020180524.pdf